BioInvent's new cancer drug BI-1910 shows promise in early trials, proving effective and safe.

BioInvent International has announced positive results from its Phase 1 study of BI-1910, a new treatment for solid tumors. The drug showed promise when used alone, with encouraging data on its effectiveness and safety profile. This early-stage trial is a step towards potential future clinical applications for cancer patients.

2 months ago
3 Articles